Better Therapeutics EBIT

Better Therapeutics (BTTX) currently reports a EBIT of $-32M as of September 2023. That compares with $-42M in the prior-year period — up 24.1% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore Better Therapeutics's EBIT history and peer comparisons.

Better Therapeutics's EBIT increased from $-42M to $-32M — a 24.1% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Better Therapeutics's EBIT of $-32M is lower than the its sector sector average of $-6.4M. That is roughly 398.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Better Therapeutics reported $-32M in EBIT as of September 2023. That compares with $-42M in the prior-year period — up 24.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-32M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for Better Therapeutics, and consider following BTTX for alerts when major investors trade the stock.